Bellicum Pharmaceuticals Inc (BLCM)

NASDAQ
0.330
+0.018(+5.77%)
  • Volume:
    202,261
  • Day's Range:
    0.308 - 0.364
  • 52 wk Range:
    0.230 - 2.200
Earnings results expected today

Bellicum Pharmaceuticals Inc will announce its quarterly financial results today. Traders should take this into account as the share price often fluctuates around this time period.

BLCM Overview

Prev. Close
0.295
Day's Range
0.308-0.364
Revenue
1M
Open
0.308
52 wk Range
0.23-2.2
EPS
-0.6
Volume
202,261
Market Cap
2.84M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
100,559
P/E Ratio
-0.57
Beta
1.56
1-Year Change
-84.72%
Shares Outstanding
8,613,527
Next Earnings Date
Mar 31, 2023
What is your sentiment on Bellicum Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Bellicum Pharmaceuticals Inc Company Profile

Bellicum Pharmaceuticals Inc Company Profile

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. The Company has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). It uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. Its product candidates include BPX-601 and BPX-603. BPX-601, is an autologous GoCAR-T product candidate containing inducible MyD88/CD40 (iMC) activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). BPX-603 is its dual-switch GoCAR-T product candidate and is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong BuyStrong SellStrong Sell
SummaryStrong SellStrong SellNeutralStrong SellStrong Sell
  • With today volume can this reach 20$ ?
    0
    • its on !⚡⚡
      0
      • the worst stock ever
        1
        • Achteruitgang van het aandeel,  in de naverkoop nochtans zien de . Kandelaarpatronen er zeer positief uit, of is het om eerst de prijs van het aandeel naar beneden te drukken alvorens men weder koopt?
          0
          • This the worst low volume bio stock to own because it trades regardless of news, usually opposite of good news, lost 70% value since ASH meeting despite no negative news, hardly gained 20% while ZIOP nearly tripled without news.
            0
            • What are people thinking about the return of this stock?
              1
              • $BLCM: Buy this stock before the big news!
                1
                • I bought this stock on the recommendation of a paid investment adviser. Since I bought the stock it is down about 15%. I was told that the stock was set to explode after a meeting it had with top pharmaceutical companies a few weeks ago to discuss some phase 2 test results. Supposedly the stock was set to "explode" in price after this meeting. Since then I have head nothing and he stock price has slowly gone down. The excuse is that the stock is in an overbought position. If the results of the phase 2 tests wee so good why haven't I heard about hem in the news media? That is what is needed to drive this stock. Otherwise, let me know what the status is so that I can invest my money somewhere else.
                  0
                  • It is going to explode. Hold your shares
                    0